<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03781726</url>
  </required_header>
  <id_info>
    <org_study_id>2018P003140</org_study_id>
    <nct_id>NCT03781726</nct_id>
  </id_info>
  <brief_title>Multi-center Study to Transplant Hepatitis-C Infected Kidneys</brief_title>
  <acronym>MYTHIC</acronym>
  <official_title>A Multi-Center, Open-Label Study of Glecaprevir/Pibrentasvir to Treat Recipients of Transplanted Kidneys From Deceased Donors With Hepatitis C Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raymond Chung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label multi center study for the donation of HCV positive kidneys to HCV negative
      recipients with interventional treatment to prevent HCV transmission upon transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to determine if the administration of the direct acting antiviral
      glecaprevir/pibrentasvir for 8 weeks after kidney transplantation is both safe and effective
      at preventing the spread of HCV infection from donor kidney with known HCV infection (all
      genotypes) to an HCV negative recipient as evidenced by a negative HCV viral RNA at 12 weeks
      post treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>HCV RNA &lt; LLOQ 12 weeks after the last actual dose of G/P</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with on-treatment virologic failure</measure>
    <time_frame>During 8 week treatment course</time_frame>
    <description>HCV RNA &gt; LLOQ during G/P treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with post-treatment virologic relapse</measure>
    <time_frame>During 12 week post treatment follow-up</time_frame>
    <description>HCV RNA &gt; LLOQ after completion of G/P treatment and prior HCV RNA &lt; LLOQ while on treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Renal Failure Chronic</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment with glecaprevir/pibrentasvir Fixed Dose Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glecaprevir/pibrentasvir treatment</intervention_name>
    <description>combination treatment with glecaprevir and pibrentasvir fixed dose tablet.</description>
    <arm_group_label>Treatment with glecaprevir/pibrentasvir Fixed Dose Combination</arm_group_label>
    <other_name>Mavyret treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria:

          -  Estimated glomerular filtration rate(eGFR) &lt; 15 ml/min/1.73 m2

          -  Listed for an isolated kidney transplantation

          -  Able to understand and adhere to the study visit schedule and all other protocol
             requirements, and must voluntarily sign and date an informed consent

          -  No available medically acceptable, compatible living kidney donor

          -  Subject must agree to use an effective method of birth control per protocol
             specifications

        Recipient Exclusion Criteria:

          -  History of severe, life-threatening or other significant sensitivity to
             immunosuppressants utilized in kidney transplant

          -  Female who is pregnant, breastfeeding, or is planning to become pregnant during the
             course of the study

          -  History of HIV

          -  HCV RNA positive

          -  HBV surface Ag-positive or detectable HBV DNA

          -  Primary focal segmental glomerulosclerosis (FSGS) or disease process with increased
             risk of causing early graft failure as assessed by the transplant nephrologist and/or
             investigator team

          -  Presence of clinically significant liver disease

          -  Transplant candidate requiring antibody desensitization protocol for transplantation

          -  Most recent calculated panel reactive antibody (cPRA) &gt;80%.

          -  Prior recipient of a non-renal solid organ transplant

        Donor Organ Inclusion Criteria

          -  Deceased donor organ with kidney donor profile index (KDPI) â‰¤0.85

          -  HCV RNA-positive

        Donor Organ Exclusion Criteria

          -  Known prior HCV treatment with direct acting antiviral medication

          -  HIV RNA-positive

          -  HBV Surface antigen-positive or HBV DNA-positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond T Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Raymond Chung</investigator_full_name>
    <investigator_title>Director of Hepatology</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>renal failure</keyword>
  <keyword>kidney transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Coded data is anticipated to be shared with collaborators in this multi-center consortium</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Real time</ipd_time_frame>
    <ipd_access_criteria>researchers accessing IPD must be an approved site within the consortium.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

